What does your role at BIA involve?

Steve Bates FMed Sci OBE has been leading the UK Bioindustry Association as CEO since 2012. He currently chairs the International Council of Biotech Associations and has been a board member of EuropaBio since 2015. He sits on the UK’s Life Sciences Council. Steve is the visible face of the vibrant UK life sciences industry to government and media. Steve was a founder member of the UK Government’s Vaccine Taskforce in the Covid crisis, sitting on its steering Board alongside Kate Bingham.

Previous experience & achievements

Steve has championed, with government, effective industrial incentives like the Biomedical Catalyst, which have crowded in private sector investment into UK SMEs. He has forged several links for the sector across the USA, Europe and in China. In his time at the BIA, Steve has developed new member groups focused on cell and gene therapy, genomics and engineered biology. A strong advocate of partnership working, Steve champions sector collaboration with research charities and academia. Proud to lead an organisation with a diverse Board with over 40% female representation, Steve is committed to next-generation talent and developing the skills needed for the sector to flourish. Before the BIA, Steve worked for Genzyme and was an advisor to the UK Government of Tony Blair. He was made OBE for services to innovation in 2017 and became a Fellow of the Academy of Medical Science in 2020.

• Email Address

  [email protected]

• Phone number

  020 7630 2180

Dave joined CPI in January 2019 as Managing Director for the Medicines Manufacturing Innovation Centre (MMIC).

The MMIC is a collaboration between industry, academia and government. CPI is working together with the University of Strathclyde, AstraZeneca and GSK. With government support from Scottish Enterprise and Innovate UK, the MMIC will be located in Renfrewshire, Scotland.

The MMIC is a unique facility to enable new and disruptive pharmaceutical manufacturing technologies to be proven at scale in a GMP-capable environment. This will speed next-generation process adoption with reduced risk, cost and time, and provide a unique environment for the training of personnel in the techniques of future manufacturing processes.

Prior to this Dave worked for GSK, joining in 1992 as a PhD Chemist from Glasgow University. He has over 20 years’ experience with the company carrying out a number of Technical, Compliance and Manufacturing leadership roles, before becoming VP Head of GMS Strategy in 2017, with responsibility for manufacturing strategy, deployment of strategic programmes, performance management and advocacy.

He plays an active role with a number of Governments and is currently co-chair of the Life Sciences Scotland Industry Leadership Group.

Dave is married with 4 children and lives in Ayrshire. He enjoys all sports, particularly football, is a keen reader of Scottish history and cooks to relax.

What does your role at BIA involve?

Steve Bates FMed Sci OBE has been leading the UK Bioindustry Association as CEO since 2012. He currently chairs the International Council of Biotech Associations and has been a board member of EuropaBio since 2015. He sits on the UK’s Life Sciences Council. Steve is the visible face of the vibrant UK life sciences industry to government and media. Steve was a founder member of the UK Government’s Vaccine Taskforce in the Covid crisis, sitting on its steering Board alongside Kate Bingham.

Previous experience & achievements

Steve has championed, with government, effective industrial incentives like the Biomedical Catalyst, which have crowded in private sector investment into UK SMEs. He has forged several links for the sector across the USA, Europe and in China. In his time at the BIA, Steve has developed new member groups focused on cell and gene therapy, genomics and engineered biology. A strong advocate of partnership working, Steve champions sector collaboration with research charities and academia. Proud to lead an organisation with a diverse Board with over 40% female representation, Steve is committed to next-generation talent and developing the skills needed for the sector to flourish. Before the BIA, Steve worked for Genzyme and was an advisor to the UK Government of Tony Blair. He was made OBE for services to innovation in 2017 and became a Fellow of the Academy of Medical Science in 2020.

• Email Address

  [email protected]

• Phone number

  020 7630 2180

Kit is responsible for strategy development and implementation of major site projects at FUJIFILM Diosynth Biotechnologies in the UK. Kit has also worked as a Biochemical Engineer for 15 years and holds a Lean Six Sigma leader Master Black Belt qualification. He has applied LSS to quality, engineering and manufacturing in the course of leading laboratory refurbishment and transformational office construction projects totalling more than £80M. Kit has a first degree from Nottingham University in Chemical Engineering and a PhD from Cambridge University in Chemical Engineering and is a Fellow of the Institute of Chemical Engineers. He is studying for a MBA with the Open University as part of the ATAC programme.

What does your role at BIA involve?

Steve Bates FMed Sci OBE has been leading the UK Bioindustry Association as CEO since 2012. He currently chairs the International Council of Biotech Associations and has been a board member of EuropaBio since 2015. He sits on the UK’s Life Sciences Council. Steve is the visible face of the vibrant UK life sciences industry to government and media. Steve was a founder member of the UK Government’s Vaccine Taskforce in the Covid crisis, sitting on its steering Board alongside Kate Bingham.

Previous experience & achievements

Steve has championed, with government, effective industrial incentives like the Biomedical Catalyst, which have crowded in private sector investment into UK SMEs. He has forged several links for the sector across the USA, Europe and in China. In his time at the BIA, Steve has developed new member groups focused on cell and gene therapy, genomics and engineered biology. A strong advocate of partnership working, Steve champions sector collaboration with research charities and academia. Proud to lead an organisation with a diverse Board with over 40% female representation, Steve is committed to next-generation talent and developing the skills needed for the sector to flourish. Before the BIA, Steve worked for Genzyme and was an advisor to the UK Government of Tony Blair. He was made OBE for services to innovation in 2017 and became a Fellow of the Academy of Medical Science in 2020.

• Email Address

  [email protected]

• Phone number

  020 7630 2180

Chair of RoslinCT and Chair of Cell and Gene Therapy Catapult; Chair of Manufacturing Advisory Group for IUK Industrial Challenge Fund; Member of the UK Government Vaccines Task Force.

Ian retired from his role as SVP North America, Japan & Global Pharma Supply, GSK in April 2017. He joined GSK in 2006, his second spell with the company and was responsible for 17 factories and 7,000 employees globally whose role within GSK was to supply the New Product pipeline and the majority of GSK's pharmaceutical sales.

Ian chaired the Advanced Therapy Manufacturing Task Force originally co-chaired with George Freeman, Minister for Life Sciences and the group published its Action Plan to 'anchor' commercial scale manufacturing in the UK. The Action Plan has subsequently been adopted in full as part of the Life Sciences Industrial Strategy. He led the manufacturing work stream of the UK Vaccines Task Force between March 2020 and May 2021.

Ian is a pharmacist with 40 years of experience in the Pharmaceutical industry working for GSK, Merck Generics and IVAX. His core capability is in the field of manufacturing and supply chain leadership and new product introduction. His passion is cell and gene therapies due to their transformational medical benefits and the opportunity they create for UK economic benefit.

Cath Green is Head of the Clinical Biomanufacturing Facility at the University of Oxford. As a unique GMP manufacturing facility embedded in a world-leading academic research institution, the CBF endeavours to assist basic researchers in the transition from pre-clinical studies to first in man human trials. We are currently mostly producing adenovirus vectored vaccines against major human pathogens, but also have significant experience in recombinant protein and monoclonal antibody production. The CBF holds an MIA from the MHRA for manufacture and importation of IMPs and has in house QC and QP teams to ensure our products are of the highest quality. Cath is also both an Associate Professor in the Nuffield Department of Medicine, Oxford, where she heads a research team within the Wellcome Centre for Human Genetics, and a Fellow of Exeter College, Oxford.

Kit is responsible for strategy development and implementation of major site projects at FUJIFILM Diosynth Biotechnologies in the UK. Kit has also worked as a Biochemical Engineer for 15 years and holds a Lean Six Sigma leader Master Black Belt qualification. He has applied LSS to quality, engineering and manufacturing in the course of leading laboratory refurbishment and transformational office construction projects totalling more than £80M. Kit has a first degree from Nottingham University in Chemical Engineering and a PhD from Cambridge University in Chemical Engineering and is a Fellow of the Institute of Chemical Engineers. He is studying for a MBA with the Open University as part of the ATAC programme.

What does your role at BIA involve?

As an experienced Biochemical Engineer, Kate leads skills and talent programme development across STEM industries using over 30 years of experience within large pharma and small company networks. Working with BIA, she represents the sector ensuring access to the incredible talent and addressing skills gaps to start, grow and scale innovative life sciences and biotech organisations.


Previous experience & achievements

In addition to her role at BIA, Kate works as an independent consultant supporting organisations to develop their skills and talent strategies. She has oversight for quality governance of technical and professional education as IfATE Non-Executive Director and is a Board member of North Hertfordshire College. Kate holds MBA from Open University and a PhD in Bio-Chemical Engineering from UCL. As a Chartered Engineer (CEng FIChemE), she held previous senior leadership roles across diverse pharmaceutical manufacturing and R&D portfolios including Solid Dose, Parenteral & Inhaled Devices.


If you could invite any scientist or entrepreneur to dinner, who would it be and why?

Rosalind Franklin, as she made contributions to the understanding of the fine molecular structures of DNA and RNA. She studied science at a time when few women attended university and led pioneering work on multiple viruses. Kate would love to know what she thinks about what we know now!

• Email Address

  [email protected]

• Phone number

  07875 155856

Professor Nora Colton is the Director of the UCL Global Business School of Health. She is a health and development economist with extensive experience in change management and strategy. Her current focus is on senior teams in healthcare organisations, where her research explores upper echelons theory, examining the relationship between senior leaders and organisational performance in healthcare organisations. Before her current role, Professor Colton was the UCL Pro-Vice-Provost (Postgraduate Education). She has been a Professor of International Economics at Drew University, USA; Dean of Business and Deputy Vice Chancellor at University of East London (UEL), UK; and a visiting professor in the School of Public Administration at the University of Electronic Science and Technology (UESTC), Chengdu, China as well as the American University in Beirut (AUB), Lebanon. Professor Colton holds a doctorate from the University of Oxford, UK.

Following her studies in Biochemical Engineering in France, Hélène Trottin started her career in the UK focussing on the optimisation of microbial upstream processes for the production of recombinant protein. She has worked as a Scientist and Senior Scientist on various projects in early and late stage development. She is currently working as Senior Technical Specialist at Allergan Biologics in Liverpool, where she is leading the technical transfer of Gene Therapy processes from development to GMP manufacturing.

Jacqui joined Cambridge Antibody Technology (later MedImmune, then AstraZeneca) in 2006 to establish a project leadership and management group. Following reorganisation in 2010, Jacqui led a number of change initiatives to establish principles for the transition of medicines from early to late-stage clinical development. In 2011, Jacqui set up the Scientific Learning team at MedImmune, responsible for scientific training, as well as wider learning and development.

In her current role at AstraZeneca, Jacqui leads the Early Careers team in Research and Development, focussed on building global, high quality programmes for apprentices, graduates, undergraduates, PhD students and post-doctoral researchers. She is a Board member of the Science Industry Partnership and leads the Futures group for skills delivery. She is also a member of the UKRI-BBSRC People and Talent Strategy Advisory Panel.

Prior to joining AstraZeneca, Jacqui spent over 17 years working in clinical development and project leadership roles at Schering-Plough, PPD and GlaxoSmithKline.
Jacqui holds a first class honours degree in Chemistry from the University of London and a postgraduate diploma in Clinical Science from the University of Wales. She is a fellow of the Royal Society of Biology and the Institute of Innovation and Knowledge Exchange.

Tina is the Managing Director of MedAnnex and sits on MedAnnex’s Executive Team and Scientific Advisory Board.

Tina has a PhD in pharmaceutics and has worked in pharmaceutical and biotechnology R&D for over 25 years. A Principal in PwC’s Pharmaceutical Industry Group, since 2002 she has worked in a management and advisory capacity in the biopharmaceutical sector; her clients have included Wyeth Biopharma/Pfizer Biotechnology, Novartis Biotechnology Centre, Celltech/UCB, Sanofi Aventis, Roche and CAT/MedImmune/AZ. From 2009 to 2014 Tina worked with Prosensa Therapeutics, a rare disease company in RNA modulation technology, where she led the business side of the company’s float on NASDAQ in 2013. As Vice President responsible for the development portfolio and alliances, Tina oversaw the development pipeline and out-licensing, with strategic partners in academia, industry and patient organisations, and the progress of Prosensa’s lead programme towards regulatory market submissions. Tina has been working with Edinburgh-based MedAnnex Ltd since 2015.

Peter Levison has a career spanning over 30 years within the Biotechnology Industry. His background is Process Chromatography and spent many years within various R&D leadership roles responsible for the development and technical support of chromatography resins and membranes as well as columns and related chromatography hardware at both Whatman International and Pall Corporation. During the latter stages of his career, Peter moved into a Marketing Leadership role initially leading the Product Management team for Downstream Processing and introducing an end-to-end scalable Continuous Bioprocessing platform. Finally, he was responsible for developing strategic partnerships and collaborations within the Biotech community through the management of a network of Global Thought Leaders and collaborative partners by working with key industrialists and academics around the world, Peter retired in May 2022 and now spends time enjoying life and having the ability to do the activities that full-time work impedes.
Peter has always been an advocate of networking and mentoring and continues to maintain relationships with the academic community, the research councils and the BIA to support the development of early career researchers.
Peter holds a BSc (Hons) Class I in Biochemistry from the University of Manchester, Manchester, UK and a PhD gained in the Dept. of Biochemistry, University of Manchester. He has an MBA awarded through the Open University Business School, Milton Keynes, UK

What does your role at BIA involve?

Nick is responsible for overseeing the BIA’s operations, ensuring that all activities are professionally delivered to the highest standard and providing an organisation-wide operational perspective to and support for, activities and projects. He has specific responsibility for office management/facilities; financial systems/processes and credit control; the people, skills and talent workstream; company secretariat; human resources and IT/telecoms.


Previous experience & achievements

Nick has extensive industry and not-for-profit management experience. Prior to this role, he ran the Clinical Laboratory Division of Lab21. This involved providing specialist laboratory services to the healthcare, pharmaceutical and clinical trials markets. In that role, Nick had management responsibility for all operations, income, laboratory and customer services and client liaison across the Group. He also has specific and extensive experience of diagnostic testing within the HIV and HCV disease areas. This was gained through building Delphic Diagnostics into a one-stop shop for clinicians, enabling more effective patient monitoring and subsequent treatment options. Nick also has broad management experience within the not-for-profit and charity sector, working for a trade body representing and building the profile of the business communication industry and prior to that working for the world’s oldest active society devoted to natural history.


If you could invite any scientist or entrepreneur to dinner, who would it be?

Alfred Russel Wallace, a naturalist, explorer, geographer, anthropologist, biologist and illustrator, independently conceived the theory of evolution through natural selection. He travelled the world and I would imagine had some excellent stories to tell.

• Email Address

  [email protected]

• Phone number

  07469 140588

Pharmaceutical Science is responsible for all small molecule development activities from molecular design in research through to global registration and commercial launch. I currently chair the Medicines Manufacturing Industrial Partnership, Pfizer lead on ABPI’s New Medicines and Data Strategic Leadership Group and a Professor of Pharmaceutics at the University of Nottingham.
After my first degree in Pharmacy at the University of Manchester, I worked in community Pharmacy and then completed a drug delivery based PhD at the University of Nottingham. I worked at GSK in the discovery drug metabolism group before moving to Pfizer to set up a new Pharmaceutical Sciences Discovery support function.
I have led the Global Drug Product Design group, also been the Pharmaceutical Sciences Research leader for the A&R, Pain and GI/GU Research units and a member of the Global Clinical Research leadership team. In addition, I have led Pharmaceutical Science’s intellectual property activities and due diligence for merger and acquisitions.

Juliette White is VP for Global Sustainability and SHE, based in UK, and has 32 years’ service with AZ.
Juliette graduated with a degree in Psychology and during her time with the Company has held a wide number of HR roles both in UK and US, including various Supply Chain roles within Operations. Juliette has a breadth of experience in HR leadership roles both Centre of Excellence and shared service roles, and also as VP for HR for Operations and our Enabling Functions. Prior to moving into the Sustainability role, Juliette led our organisation responsible for all our commercial external supply chains, managing a network of over 200 CMOs covering all aspects of our portfolio and across a wide range of technology basis, ensuring supply and value for AZ.
Juliette has been lead the AZ Supply Chain response to Brexit preparations, and for the last 2 years has been lead the UK Crisis team in response to COVID19, ensuring the safety of all our staff in UK, and continued supply of medicines. She was awarded a CBE in the Queen’s Birthday honours in June 2021.
In her role within Sustainability, Juliette holds accountability for our Carbon Zero programme across the enterprise and leads a number of our external efforts and engagements on Sustainability. In addition provides leadership to the cross functional UK Governance team with close engagement in our UK Government.
Juliette is based in North West of UK where she lives with her husband and has 3 grown up children and 2 dogs!.

What does your role at BIA involve?

Steve Bates FMed Sci OBE has been leading the UK Bioindustry Association as CEO since 2012. He currently chairs the International Council of Biotech Associations and has been a board member of EuropaBio since 2015. He sits on the UK’s Life Sciences Council. Steve is the visible face of the vibrant UK life sciences industry to government and media. Steve was a founder member of the UK Government’s Vaccine Taskforce in the Covid crisis, sitting on its steering Board alongside Kate Bingham.

Previous experience & achievements

Steve has championed, with government, effective industrial incentives like the Biomedical Catalyst, which have crowded in private sector investment into UK SMEs. He has forged several links for the sector across the USA, Europe and in China. In his time at the BIA, Steve has developed new member groups focused on cell and gene therapy, genomics and engineered biology. A strong advocate of partnership working, Steve champions sector collaboration with research charities and academia. Proud to lead an organisation with a diverse Board with over 40% female representation, Steve is committed to next-generation talent and developing the skills needed for the sector to flourish. Before the BIA, Steve worked for Genzyme and was an advisor to the UK Government of Tony Blair. He was made OBE for services to innovation in 2017 and became a Fellow of the Academy of Medical Science in 2020.

• Email Address

  [email protected]

• Phone number

  020 7630 2180